Johnson & Johnson (JNJ) of New Brunswick, based in New Jersey, is engaged in research and development, manufacturing and sale of various products in the world of health care. With a market capitalization of $ 366.4 billion, the company operates thanks to its innovative medicine and medtech segments.
The major health care should unveil its second quarter results before the markets open on Wednesday July 16. Before the event, analysts expect JNJ to declare a non-gap profit of $ 2.65 per share, down 6% compared to the benefit of $ 2.82 per share declared during the quarter of the year of the year. On a positive note, the company has exceeded the end of the street projections during each of the last four quarters.
For full financial year, its profits should reach $ 10.60 per share, up 6.2%, against $ 9.98 per share declared in the previous quarter of the year. During the year 2026, its profits should increase by 3.6% in annual sliding to $ 10.98 per share.
The JNJ action has increased by 3.5% in the past 52 weeks, outperforming the drop of 8.1% in the SPDR SECTOR SPDR health care sector (XLV), but lagging behind the increase in the S&P 500 index ($ SPX) 12.1% in the same period of time.
Despite the delivery of better than expected finance, Johnson & Johnson’s equity prices observed a marginal drop after the publication of its first quarter results on April 15. Taken by solid American sales growth, the company’s overall head line for the quarter increased by 2.4% in annual sliding to $ 21.9 billion, exceeding the street expectations of 1.3%. Meanwhile, the company’s adjusted BPA increased 2.2% in annual sliding to $ 2.77, exceeding consensual estimates by 7.8%. On an even more positive note, the free cash flows of JNJ jumped from 19.3% in annual sliding to 3.4 billion dollars. After the initial decline, JNJ’s shares rebounded and remained green for the two following negotiation sessions.
The opinion of the consensus on JNJ is prudently optimistic, with a note “buy moderate” overall. Of the 23 analysts covering the stock, opinions include nine “strong purchases”, two “moderate purchases” and 12 “holders”. Its average price objective of $ 169.14 suggests a potential of increase of 11.3% of current price levels.
On the date of publication, Aditya Sarawgi had (directly or indirectly) positions in any of the titles mentioned in this article. All information and data of this article are only for information purposes. This article was initially published on Barchart.com
